Author:
Rosenblum Hannah G.,Wallace Megan,Godfrey Monica,Roper Lauren E.,Hall Elisha,Fleming-Dutra Katherine E.,Link-Gelles Ruth,Pilishvili Tamara,Williams Jennifer,Moulia Danielle L.,Brooks Oliver,Talbot H. Keipp,Lee Grace M.,Bell Beth P.,Daley Matthew F.,Meyer Sarah,Oliver Sara E.,Twentyman Evelyn
Publisher
Centers for Disease Control MMWR Office
Subject
Health Information Management,Health, Toxicology and Mutagenesis,General Medicine,Health (social science),Epidemiology
Reference7 articles.
1. Food and Drug Administration. COVID-19 vaccines authorized for emergency use or FDA-approved. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
2. Food and Drug Administration; Vaccines and Related Biological Products Advisory Committee. Event materials. Presented at the Vaccines and Related Biological Products Advisory Committee meeting. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; June 28, 2022. https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-products-advisory-committee-june-28-2022-meeting-announcement#event-materials
3. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated—VISION Network, 10 states, December 2021–June 2022.;Link-Gelles;MMWR Morb Mortal Wkly Rep,2022
4. Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage period.;Link-Gelles;medRxiv
5. CDC; Advisory Committee on Immunization Practices. ACIP presentation slides: September 1, 2022 meeting. Presented at the Advisory Committee on Immunization Practices meeting. Atlanta, GA: US Department of Health and Human Services, CDC; September 1, 2022. https://www.cdc.gov/vaccines/acip/meetings/slides-2022-09-01-02.html